CMB International Capital

CMB International Capital is the offshore investment arm of China Merchants Bank, operating from Hong Kong with significant capacity to fund advanced healthcare and AI enterprises. The firm sits within one of China’s largest commercial banking groups, which gives it both the balance sheet and the institutional relationships to underwrite growth-stage investments at meaningful scale.

The thesis covers biotech, medical devices and medtech, and pharma and therapeutics, with explicit AI focus across those categories. CMB International Capital invests where there is credible commercial traction and a path to scale within China and across Asian markets, often alongside the broader China Merchants Bank ecosystem. The healthcare investments tend toward clinical-stage assets and growth-stage healthcare technology businesses rather than early science platforms.

The firm writes $5M to $25M checks and is active from Series A through Growth, with most activity concentrated at Series B and later where its growth-investing capabilities are most relevant. Geographic focus is Greater China and Asia, with preference for companies that have meaningful exposure to Chinese markets either through operations, supply chain, or commercial customers. Founders raising early seed rounds should look to specialist healthcare seed investors instead.

The team operates within the China Merchants Bank international franchise and benefits from access to corporate banking relationships, cross-border financing capabilities, and the broader CMB platform’s institutional reach. Specific partner names are not provided in the source data, so founders should engage through CMBI’s main channels and expect routing through institutional relationship channels rather than open inbound venture pitch processes.

The approach is institutionally rigorous and growth-focused. CMB International Capital expects clear unit economics, credible paths to scale, and management teams that can operate through the governance demands of a large institutional investor. The firm is a strong fit for growth-stage healthcare and AI companies with meaningful China exposure that benefit from a commercial banking anchor investor. Founders building purely Western-focused businesses or those at early seed stages will be a poor structural fit.